NASDAQ:IMMP Immutep (IMMP) Stock Forecast, Price & News $2.13 -0.17 (-7.39%) (As of 05/26/2023 04:00 PM ET) Add Compare Share Share Today's Range$2.06▼$2.2350-Day Range$1.54▼$2.6252-Week Range$1.47▼$3.90Volume646,800 shsAverage Volume1.00 million shsMarket Capitalization$187.29 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Immutep MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside369.5% Upside$10.00 Price TargetShort InterestHealthy0.89% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.38) to ($0.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.54 out of 5 starsMedical Sector929th out of 1,010 stocksPharmaceutical Preparations Industry464th out of 494 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Immutep has a forecasted upside of 369.5% from its current price of $2.13.Amount of Analyst CoverageImmutep has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.89% of the outstanding shares of Immutep have been sold short.Short Interest Ratio / Days to CoverImmutep has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immutep has recently decreased by 0.40%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImmutep does not currently pay a dividend.Dividend GrowthImmutep does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMMP. Previous Next 3.9 News and Social Media Coverage News SentimentImmutep has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Immutep this week, compared to 1 article on an average week.Search Interest14 people have searched for IMMP on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Immutep to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immutep insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.07% of the stock of Immutep is held by insiders.Percentage Held by InstitutionsOnly 6.06% of the stock of Immutep is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immutep are expected to decrease in the coming year, from ($0.38) to ($0.49) per share.Price to Book Value per Share RatioImmutep has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Immutep (NASDAQ:IMMP) StockImmutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.Read More Receive IMMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMP Stock News HeadlinesMay 29, 2023 | americanbankingnews.comComparing Immutep (NASDAQ:IMMP) & Vaccitech (NASDAQ:VACC)May 21, 2023 | americanbankingnews.comMaxim Group Boosts Immutep (NASDAQ:IMMP) Price Target to $10.00May 29, 2023 | Stocks To Trade (Ad)3 Free Stock Picks per DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 18, 2023 | msn.comMaxim Group Maintains Buy Rating for Immutep: Here's What You Need To KnowMay 18, 2023 | finance.yahoo.comImmutep (IMMP) Surges 65% on Upbeat Lung Cancer Study DataMay 17, 2023 | msn.comImmutep Soars with New Cancer TreatmentMay 17, 2023 | msn.comImmutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 TrialMay 16, 2023 | finance.yahoo.comImmutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung CancerMay 29, 2023 | Stocks To Trade (Ad)3 Free Stock Picks per DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 12, 2023 | americanbankingnews.comImmutep (NASDAQ:IMMP) Stock Crosses Below 50 Day Moving Average of $1.67May 2, 2023 | finance.yahoo.comImmutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell CarcinomaApril 26, 2023 | finance.yahoo.comImmutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual MeetingApril 20, 2023 | americanbankingnews.comImmutep (NASDAQ:IMMP) Stock Price Crosses Below 50 Day Moving Average of $1.71November 10, 2022 | finance.yahoo.comImmutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022November 9, 2022 | finance.yahoo.comImmutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy CombinationNovember 4, 2022 | finance.yahoo.comImmutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press ConferenceOctober 7, 2022 | globenewswire.comImmutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting - GlobeNewswireOctober 7, 2022 | marketscreener.comImmutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 2022 Annual Meeting - Marketscreener.comOctober 4, 2022 | marketscreener.comImmutep Says US FDA Awarded Fast Track Designation for Proposed Treatment of First-Line Non-Small Cell Lung Cancer - Marketscreener.comOctober 4, 2022 | seekingalpha.comImmutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype - Seeking AlphaOctober 4, 2022 | globenewswire.comImmutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer - GlobeNewswireOctober 4, 2022 | finance.yahoo.comImmutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung CancerOctober 4, 2022 | marketscreener.comWilsons Equity Research - Immutep Limited (IMM) | FastTrack for Efti in 1st line NSCLC (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey) - Marketscreener.comOctober 4, 2022 | marketscreener.comImmutep Gains US FDA Fast Track Designation for Immunotherapy Drug; Shares Jump 8% - Marketscreener.comSeptember 26, 2022 | globenewswire.comImmutep to Participate in Two Upcoming Investor Conferences - GlobeNewswireSeptember 26, 2022 | finance.yahoo.comImmutep to Participate in Two Upcoming Investor ConferencesSeptember 23, 2022 | marketscreener.comImmutep Gets $1.8 Million Research and Development Incentive from France - Marketscreener.comSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IMMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immutep and its competitors with MarketBeat's FREE daily newsletter. Email Address IMMP Company Calendar Today5/29/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMMP CUSIPN/A CIK1506184 Webwww.immutep.com Phone(128) 315-7003Fax61-2-8569-1880Employees2,021Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+369.5%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.01 Current Ratio8.97 Quick RatioN/A Sales & Book Value Annual Sales$170,369.00 Price / Sales1,099.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book2.70Miscellaneous Outstanding Shares87,930,000Free Float85,231,000Market Cap$187.29 million OptionableNot Optionable Beta2.39 Key ExecutivesMarc VoigtChief Executive Officer, CFO & Executive DirectorDeanne MillerCOO, Secretary & General CounselDavid FangFinance Director & Assistant SecretaryFlorian D. VoglChief Medical OfficerChristian MuellerVice President-Strategic DevelopmentKey CompetitorsImmuneeringNASDAQ:IMRXCara TherapeuticsNASDAQ:CARAAadi BioscienceNASDAQ:AADIADC TherapeuticsNYSE:ADCTZevra TherapeuticsNASDAQ:ZVRAView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 2,000 shares on 5/16/2023Ownership: 0.000%Dimensional Fund Advisors LPBought 10,813 shares on 5/12/2023Ownership: 0.093%Group One Trading L.P.Bought 2,300 shares on 5/12/2023Ownership: 0.000%Simplex Trading LLCSold 19,300 shares on 4/27/2023Ownership: 0.000%OLD Mission Capital LLCBought 21,158 shares on 3/6/2023Ownership: 0.024%View All Institutional Transactions IMMP Stock - Frequently Asked Questions What is Immutep's stock price forecast for 2023? 0 Wall Street analysts have issued twelve-month target prices for Immutep's stock. Their IMMP share price forecasts range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 369.5% from the stock's current price. View analysts price targets for IMMP or view top-rated stocks among Wall Street analysts. How have IMMP shares performed in 2023? Immutep's stock was trading at $1.75 at the beginning of 2023. Since then, IMMP shares have increased by 21.7% and is now trading at $2.13. View the best growth stocks for 2023 here. What other stocks do shareholders of Immutep own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immutep investors own include Nuwellis (CHFS), MEI Pharma (MEIP), VBI Vaccines (VBIV), Vaxart (VXRT), Amarin (AMRN), Gilead Sciences (GILD), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE) and Vascular Biogenics (VBLT). What is Immutep's stock symbol? Immutep trades on the NASDAQ under the ticker symbol "IMMP." Who are Immutep's major shareholders? Immutep's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.09%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%) and Simplex Trading LLC (0.00%). How do I buy shares of Immutep? Shares of IMMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Immutep's stock price today? One share of IMMP stock can currently be purchased for approximately $2.13. How much money does Immutep make? Immutep (NASDAQ:IMMP) has a market capitalization of $187.29 million and generates $170,369.00 in revenue each year. How many employees does Immutep have? The company employs 2,021 workers across the globe. How can I contact Immutep? Immutep's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The official website for the company is www.immutep.com. The biotechnology company can be reached via phone at (128) 315-7003, via email at jay.campbell@immutep.com, or via fax at 61-2-8569-1880. This page (NASDAQ:IMMP) was last updated on 5/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.